Currently reported studies utilizing HMA-VEN for remission induction prior to allogeneic SCT
| Study . | Type . | Participating sites . | Number of patients . | 12-month NRM (%) . | 12-month CIR . | 12-month RFS (%) . | 12-month OS (%) . | Relapse (%)/median LFS (month) . | OS (months) . |
|---|---|---|---|---|---|---|---|---|---|
| Pasvolsky et al35 | Retrospective | Multicenter | 24 | 19.1 | 58 | 63 | |||
| Winters et al36 | Retrospective | Single center | 29 | 66.1 | 74.5 | ||||
| Pollyea et al37,38 | Retrospective | Single center | 21 | 11 | 80 | NR | |||
| Kennedy et al39,40 | Retrospective | Multicenter | 88 | 17 | 18 | 73 | |||
| Nizamuddin et al41 | Retrospective | Single center | 36 | 39/11.2 | 25.4 | ||||
| Rautenberg et al42 | Retrospective | Single center | 26 | 67 | 81 | NR |
| Study . | Type . | Participating sites . | Number of patients . | 12-month NRM (%) . | 12-month CIR . | 12-month RFS (%) . | 12-month OS (%) . | Relapse (%)/median LFS (month) . | OS (months) . |
|---|---|---|---|---|---|---|---|---|---|
| Pasvolsky et al35 | Retrospective | Multicenter | 24 | 19.1 | 58 | 63 | |||
| Winters et al36 | Retrospective | Single center | 29 | 66.1 | 74.5 | ||||
| Pollyea et al37,38 | Retrospective | Single center | 21 | 11 | 80 | NR | |||
| Kennedy et al39,40 | Retrospective | Multicenter | 88 | 17 | 18 | 73 | |||
| Nizamuddin et al41 | Retrospective | Single center | 36 | 39/11.2 | 25.4 | ||||
| Rautenberg et al42 | Retrospective | Single center | 26 | 67 | 81 | NR |
CIR, cumulative index of relapse; NR, not reached; NRM, onrelapse mortality; RFS, relapse free survival; LFS, leukemia free survival.